Tango Therapeutics, Inc. (TNGX)
12.90
+0.02
(+0.16%)
USD |
NASDAQ |
Feb 25, 10:57
Tango Therapeutics Research and Development Expense (Quarterly) : 30.26M for Sept. 30, 2025
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| AbbVie, Inc. | 2.579B |
| Teleflex, Inc. | 57.23M |
| Recursion Pharmaceuticals, Inc. | 107.66M |
| Amicus Therapeutics, Inc. | 23.74M |
| EyePoint Plc | 47.75M |